Parkman Healthcare Partners’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Parkman Healthcare Partners’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-171,075	Closed	-$1.86M	–	115
2023 Q2	$1.86M	Sell	171,075 -78,925	-32%	-$676K	0.32%	77
2023 Q1	$1.73M	Buy	+250,000	New	+$1.57M	0.38%	61
2020 Q3	–	Sell	-25,000	Closed	-$254K	–	95
2020 Q2	$254K	Buy	+25,000	New	+$230K	0.07%	78

Other funds holding MRNS

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Parkman Healthcare Partners's MRNS Position: Q3 2023 in Review

Parkman Healthcare Partners sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2023, closing a stake of 171,075 shares — an estimated $1.86M sold.

Parkman Healthcare Partners first reported a position in MRNS in Q2 2020 and held it in 3 quarters. The position peaked at $1.86M in Q2 2023. 104 funds tracked by Wall St. Rank hold MRNS as of Q3 2023.

Parkman Healthcare Partners reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
Parkman Healthcare Partners sold 171,075 Marinus Pharmaceuticals, Inc shares in Q3 2023, an estimated $1.86M.
Parkman Healthcare Partners first reported a position in Marinus Pharmaceuticals, Inc in Q2 2020 and held it in 3 quarters.
Parkman Healthcare Partners's Marinus Pharmaceuticals, Inc position peaked at $1.86M in Q2 2023.
104 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2023.

Based on Parkman Healthcare Partners's 13F filing for Q3 2023, filed 14 Nov 2023.